Navigation Links
Unraveling the genetic picture of lung cancer
Date:10/22/2008

HOUSTON -- (Oct. 23, 2008) -- A study seeking possible cancer genes elucidated the mutations and the genetic pathways activated in the most common form of lung cancer lung adenocarcinoma and could lead to improved diagnosis and treatment, said the director of the Baylor College of Medicine Human Genome Sequencing Center that played a major role in the project led by the National Human Genome Research Institute.

In the report that appears in the Oct. 23 issue of the journal Nature, a national consortium of researchers called the Tumor Sequencing Project identified 26 genes that play a significant role in the development of lung adenocarcinoma as well as cellular pathways involved in the lung cancer. The analysis, involving 188 patients, more than any previous study, allowed scientists to find mutations associated with sub-types of the lung cancer such as those among non-smokers.

Lung adenocarcinoma kills an estimated 1 million people worldwide each year. As many as 10 percent of people with the disease are non-smokers. It is one of the deadliest cancers in men and women with only about 15 percent of those whom it strikes surviving five years.

The findings highlight the complexity of the disease. Along with the work from other groups which included analysis of gene expression, the mutation study undertaken by the BCM genome sequencing center and colleagues promises to unlock many of the secrets of cancer itself.

"Clearly, much still remains to be discovered. We have just begun to realize the tremendous potential of large-scale, genomic studies to unravel the many mysteries of cancer," said Dr. Richard Gibbs, a co-author of the lung adenocarcinoma paper and director of the BCM Genome Sequencing Center.

In the study, members of the consortium sequenced key candidate genes from 188 tumor samples and matching non-cancerous tissue from the same person. This approach enabled the BCM researchers to identify mutations with unprecedented sensitivity. As a result, genes such as neurofibromatosis 1 and retinoblastoma 1, and several more that had been previously associated with other cancers, were discovered to be involved in this type of lung cancer.

"Our ability to detect cancer-causing genes with such great sensitivity enabled us to create the most comprehensive map ever of how this kind of tumor is able to defeat the body's defenses against cancer," said Dr. David Wheeler, an associate professor who led the BCM genome sequencing center analysis team. "These data are likely to have very near term impact on the way physicians think about treating lung cancer."

Some anti-cancer drugs used to treat other kinds of cancers may be useful in lung as well, the researchers noted.


'/>"/>

Contact: Glenna Picton
picton@bcm.edu
713-798-4712
Baylor College of Medicine
Source:Eurekalert

Related biology technology :

1. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
2. Response Genetics Reports Second Quarter 2007 Financial Results
3. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
6. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
7. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
8. Interleukin Genetics Announces Management and Board Appointments
9. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):